PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson’s Disease Oct 6, 2021
Changing The Public’s View On Psychedelic Therapeutics With Mydecine Innovation’s Dr. Jetly Oct 1, 2021
DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 (Ibogaine) in Opioid Use Disorder Sep 21, 2021
Mindset Pharma Announces Further Preclinical Results Demonstrating Strong Efficacy and Improved Safety Profile for its… Sep 20, 2021
Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression Sep 14, 2021
PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022 Sep 13, 2021
